DSSG Group: Basket (multiple types)

Participants 18 years or older, due to receive palliative intent radiotherapy with conventional or stereotactic body radiotherapy techniques, willing to complete questionnaires with a prognosis of at least 3 months.

The purpose of this study is to understand the impact of palliative and ablative RT treatment on HRQOL in patients with metastatic disease using the electronic patient-reported outcome platform ONCOpatient. Data will be collected at 4 timepoints: at the pre-treatment, final treatment and 4-weeks and 3 months post-treatment.

Any locally advanced or metastatic cancer with taste problems.

An investigation into taste problems associated with xerostomia (dry mouth) in patients with advanced cancer.

For older persons with cancer.

The aim of the study is to evaluate the effectiveness and cost-effectiveness of a patient and family navigation intervention (NavCare-EU) for older people with cancer and declining health and their family caregivers in different healthcare systems in Europe

Metastatic or unresectable solid tumour who are eligible to receive Immune Checkpoint Inhibitor’s(ICI’s) alone or in combination with chemotherapy.

The purpose of this study is to compare the faecal microbiome pre and post ICI treatment to look got biomarkers of positive treatment response.

All cancer types known to palliative care services.

A current or prior cancer diagnosis who have clinical insomnia.

This study will examine the efficacy of digital cognitive behavioural therapy for insomnia (dCBT-I) compared to sleep hygiene education.

Cancer Associated Venous Thromboembolism

The purpose of this study is to compare the effect of abelacimab relative to apixaban on venous thromboembolism (VTE) recurrence and bleeding in patients with cancer associated VTE.

For patients with solid tumours or hematologic malignancies who are currently on treatment or in follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)

The purpose of this study is to evaluate the long-term safety and efficacy of pembrolizumab (MK-3475) in participants from previous Merck pembrolizumab-based parent studies who transition into this extension study.

All cancers (including metastatic), with the exception of brain cancers.

To assess the safety and effectiveness of a new medication in cancer patients with anorexia and weight loss.

OligoCare: patients with oligometastatic cancer who are planned to receive radical radiation therapy

ReCare: patients treated with high-dose re-irradiation for any solid organ malignancy.

The purpose of the E²-RADIatE platform is to collect real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach.